TABLE 3.
Post-discharge adverse events by time window.
| Variables | 24 h post-discharge | 24–48 h post-discharge | ||||||
|---|---|---|---|---|---|---|---|---|
| Total (n = 100) | Group D+C (n = 37) |
Group D+M (n = 63) |
P | Total (n = 80) | Group D+C (n = 53) |
Group D+M (n = 27) |
P | |
| Somnolence, n (%) | 56 (56.00) | 27 (72.97) | 29 (46.03) | 0.009 | 44 (55.00) | 34 (64.15) | 10 (37.04) | 0.021 |
| Nausea and vomiting, n (%) | 9 (9.00) | 6 (16.22) | 3 (4.76) | 0.116 | 6 (7.50) | 5 (9.43) | 1 (3.70) | 0.637 |
| Decreased appetite, n (%) | 23 (23.00) | 13 (35.14) | 10 (15.87) | 0.027 | 23 (28.75) | 18 (33.96) | 5 (18.52) | 0.149 |
| Diarrhea, n (%) | 2 (2.00) | 1 (2.70) | 1 (1.59) | 1.000 | 6 (7.50) | 5 (9.43) | 1 (3.70) | 0.637 |
| Sleep pattern disturbance, n (%) | 25 (25.00) | 13 (35.14) | 12 (19.05) | 0.073 | 23 (28.75) | 18 (33.96) | 5 (18.52) | 0.149 |
| Behavioral changes, n (%) | 26 (26.00) | 5 (13.51) | 21 (33.33) | 0.029 | 16 (20.00) | 10 (18.87) | 6 (22.22) | 0.723 |
| Ataxia, n (%) | 22 (22.00) | 13 (35.14) | 9 (14.29) | 0.015 | 16 (20.00) | 14 (26.42) | 2 (7.41) | 0.044 |
| Respiratory depression, n (%) | 4 (4.00) | 2 (5.41) | 2 (3.17) | 0.983 | 1 (1.25) | 0 (0.00) | 1 (3.70) | 0.337 |
| Dizziness, n (%) | 5 (5.00) | 4 (10.81) | 1 (1.59) | 0.117 | 3 (3.75) | 2 (3.77) | 1 (3.70) | 1.000 |
| Cough, n (%) | 7 (7.00) | 5 (13.51) | 2 (3.17) | 0.121 | 7 (8.75) | 6 (11.32) | 1 (3.70) | 0.470 |
| Return visit, n (%) | 4 (4.00) | 2 (5.41) | 2 (3.17) | 0.983 | 1 (1.25) | 1 (1.89) | 0 (0.00) | 1.000 |
| Any adverse event, n (%) | 75 (75.00) | 32 (86.49) | 43 (68.25) | 0.042 | 59 (73.75) | 43 (81.13) | 16 (59.26) | 0.036 |
Data are presented as median (interquartile range) or number (%), as appropriate.
Abbreviations: Group D+C received intranasal dexmedetomidine combined with oral chloral hydrate, and Group D+M received intranasal dexmedetomidine combined with oral midazolam.